Takara Bio Inc. Announces Unaudited Consolidated Earnings Results for the Year Ended March 31, 2020; Provides Earnings Guidance for the Six Months Ending September 30, 2020 and Full Year Ending March 31, 2021
May 14, 2020 at 07:00 am
Share
Takara Bio Inc. announced unaudited consolidated earnings results for the year ended March 31, 2020. For the year, the company reported net sales of JPY 34,565 million against JPY 35,841 million a year ago. Operating profit was JPY 6,274 million against JPY 5,463 million a year ago. Net income attributable to the owners of the parent was JPY 6,347 million against JPY 5,665 million a year ago. Net income per share was JPY 31.72 against JPY 30.38 a year ago.
For the six months ending September 30, 2020, the company expects net sales of JPY 14,365 million, operating profit of JPY 619 million.
For the year ending March 31, 2021, the company expects net sales of JPY 33,800 million, operating profit of JPY 4,500 million, net income attributable to the owners of the parent of JPY 2,600 million and net income per share of JPY 21.59 per share.
TAKARA BIO INC. is a Japan-based company principally engaged in bio-industry support business and gene medicine business. The Company operates in three business segments. Bioindustry Support segment provides reagents for research (genetic engineering reagents, cell engineering reagents, protein engineering reagents), scientific instruments, contract services and license fees for gene related patents to research institutes, such as universities and companies where biotechnology research and development are conducted. Gene Medicine segment provides gene therapy-related development and sale licensing fees and trial products as an application field of genetic engineering technology and cell engineering technology which is core technology cultivated in development of research reagents. Medical Food and Biotechnology segment provides health food and health food research and development services, license fees for health food related patents, as well as license fees for mushrooms.
Takara Bio Inc. Announces Unaudited Consolidated Earnings Results for the Year Ended March 31, 2020; Provides Earnings Guidance for the Six Months Ending September 30, 2020 and Full Year Ending March 31, 2021